Investors & Media

Transformative science, targeted medicines

We are working to advanceĀ a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

SEC Filings

SEC Filings

Filing date Form Description View
CT ORDER

CT ORDER

View HTML
3/A

An amendment to a 3 filing. Non-EDGAR filing

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML

Pagination